{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.4","upperLimit":"35.9","value":"15.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Progression-free survival is the period from study entry until disease progression, death or date of last contact. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20 % increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)","id":"OG000","title":"Pazopanib"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"6 months","title":"Percentage of Participants With Progression-free Survival (PFS) at 6 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}